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Background: Despite resistant microbes, induction immunosuppression is used in patients with cystic ﬁbrosis (CF) undergoing lung transplantation
(LTx).
Methods: To evaluate the effect of induction immunosuppression on survival, the United Network for Organ Sharing (UNOS) was queried
restricting analysis to transplant patients 6–55 years old from 2001 to 2012, who received induction agents (INDUCED) or did not (NONE).
Results: A total of 1721 CF patients who underwent LTx were included in the analysis; of these 791 (46%) were INDUCED. Of the INDUCED
patients, 65% received basiliximab, 10% alemtuzumab, and 25% thymoglobulin/anti-lymphocyte globulin/anti-thymocyte globulin. Mean age was
28.0 years (SD = 9.7) and 28.5 (SD = 9.5) for the INDUCED and NONE groups, respectively. The median survival in the INDUCED group was
93.8 months (95% CI: 73.8, --) compared to 61.8 months (95% CI: 55.8–73.8) for the NONE group (log rank p-value b0.001).
Conclusions: Antibody-based induction immunosuppression had a survival beneﬁt in CF patients undergoing LTx.
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progressively worsening obstructive lung physiology. Chronic
lung disease is the leading cause of death [1]. Lung transplan-
tation (LTx) is a therapeutic option for patients with CF and
advanced pulmonary disease [2]. The importance of LTx as a
treatment in this patient population is highlighted by the fact that
CF is the third most common indication for LTx among adults,
and is the most common indication for children older than age six
[3,4]. In addition to improved quality of life, there is a survival
benefit for LTx in adult patients with CF [5].
Chronic infection in CF airways raises numerous concerns
in the selection of these patients for LTx. The presence of
drug-resistant organisms such as Pseudomonas aeruginosa,
methicillin resistant Staphylococcus aureus (MRSA), otherll rights reserved.
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plex, fungal pathogens, and non-tuberculosis mycobacterium
species, would appear to complicate transplantation of solid
organs and place patients at significant risk for overwhelming
infection. However, multiple studies have reported successful
outcomes in CF despite these challenging infections and current
established guidelines for LTx do not list specific airway
pathogens as absolute contraindications [6–11].
Induction immunosuppression for LTx diminishes the early
recipient immune response and may decrease the incidence of
acute allograft rejection and bronchiolitis obliterans syndrome
[12]. Another benefit of induction is the ability to delay the use of
calcineurin inhibitors in the immediate post-transplant period. The
major potential complication of induction strategy is an increased
risk of infection, which is the major cause of death in the
early post-transplant period. The currently available induction
agents include: the IL-2 receptor (CD25) monoclonal antibody
Basiliximab, antithymocyte globulin which is a non-specific anti-
lymphocyte antibody, and the anti-CD52 antibody alemtuzumab
[12]. There is no clear consensus on the use and benefits of
induction immunosuppression. Thus, the choice of whether or not
to give induction and the use of specific induction agents varies
from center to center. There is evidence that the use of induction
for LTx has increased over the last decade, and now a majority of
patients are receiving some form of induction. The IL-2 receptor
antagonists are the most commonly used agents [3].
While a comprehensive analysis of United Network for Organ
Sharing (UNOS) registry data has demonstrated evidence that
induction immunosuppression has a positive effect on both graft
and overall survival in lung transplant recipients as a group, the
specific effects of induction in CF remains unclear [13]. As
patients with CF and chronic infection may theoretically be at
increased risk, we sought to evaluate the effect of contemporary
induction immunosuppression with the primary endpoint being
survival using national registry data.
2. Methods
2.1. Data collection/database
We retrospectively evaluated the outcome of CF lung
transplant recipients whose data were registered in the Organ
Procurement and Transplant Network (OPTN) Standard Trans-
plant Analysis and Research (STAR) Database [14]. With the
National Organ Transplant Act of 1984, the OPTN was
established by the Congress of the United States. UNOS is a
private, nonprofit organization that administers the OPTN under
a federal contract. The STAR database is administrated through
UNOS/OPTN as overseen by the United States Department of
Health and Human Services. The UNOS/OPTN STAR database
maintains data elements reflecting donor characteristics (e.g.,
donor mechanism of death, donor age, donor gender), pre-
transplant recipient characteristics (e.g., indication for transplan-
tation, recipient age, recipient gender), and post-transplant
recipient characteristics and outcomes (i.e., length of stay,
recipient survival, development of postoperative complication)
for solid organ transplants from 1987 to present. Data is entered atthe time of a patient's listing, and again at their time of
transplantation. The data are extracted by the individual centers
and submitted as aggregate data to the OPTN United States
Scientific Registry of Transplant Recipients (SRTR) which then
collates and manages the data per the above referenced contract.
This retrospective review was approved by The Ohio State
University Wexner Medical Center Institutional Review Board
with a waiver of the need for individual consent (IRB#
2012H0306). For purposes of this analysis, we queried the
UNOS/OPTN thoracic database for all lung transplants from
January 1, 2001 to July 6, 2011. The last status update in the
dataset was performed on 7/6/2012; therefore, the cutoff date of 7/
6/2011 was selected to allow for the potential for at least a year of
follow-up time per patient. Patients included in the study had a
diagnosis of CF, were between the ages of 6 and 55 years, and had
received cadaveric lung transplants. Patients undergoing
re-transplant were excluded. Additionally, daclizumab and OKT3
are no longer available for clinical use and therefore patients who
received either of these induction agents were excluded from the
study.We grouped the lung transplant recipients into either: having
received no induction (NONE) or having received induction
agents (INDUCED) of basiliximab, alemtuzumab, thymoglobulin
(Thymo), anti-lymphocyte globulin (ALG), or anti-thymocyte
globulin (ATG). The primary endpoint was overall survival after
transplant for patients in the INDUCED vs. NONE groups.
2.2. Statistical methods
All demographic characteristics were summarized for the
INDUCED and NONE groups separately. Kaplan–Meier
estimates of the survival function were produced to assess crude
differences in overall survival, and the log-rank test was
performed to test for differences in survival functions. Cox
proportional hazards models were used to calculate hazard ratios
(HR) and 95% confidence intervals (CI) for INDUCED vs.
NONE for both a minimally adjusted and multivariable model.
All variables included in these models were selected due to their
clinical relevance. The minimally adjusted model includes
INDUCED, recipient age at transplant and year of transplant;
the baseline hazard was also stratified by UNOS region. The
multivariable model included INDUCED, diagnosis, year of
transplant, end-match LAS, ischemic time, age, gender, chronic
steroid use, diabetes, body mass index (BMI), O2 requirement at
rest at transplant, forced expiratory volume in one second (FEV1)
% predicted at transplant, and forced vital capacity (FVC) %
predicted at transplant. In both models, interactions between
INDUCED and all other covariates were assessed using a
significance level of α = 0.01. Due to evidence of non-
proportionality, the interactions between age and year of
transplant with time (log-transformed) were included in the
model; the baseline hazard was also stratified by UNOS region.
As a sensitivity analysis to our multivariable models, we
developed a score to measure the propensity that a patient
would be induced. The following variables were used in a
logistic regression model to create the propensity score: UNOS
region, year of transplant, end match LAS, age, gender,
gender match, race, BMI, ischemic time, total bilirubin at
Table 2
Induction agent status.
Antibody based induction agent N (%)
No 930 (54%)
Yes: 791 (46%)
Basiliximab 511 (65%)
Alemtuzumab 79 (10%)
ALG/ATG/Thymoglobulin 201 (25%)
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transplant, FEV1% predicted at transplant, and FVC% predicted
at transplant. From the logistic model, a propensity score was
estimated for each patient and a total of 616 induced patients were
matched to 616 patients without induction using nearest neighbor
matching without replacement and a conservative caliper of 0.2.
We checked for balance of all covariates listed in Table 1 (for
categorical variables, we compared the proportion in each level)
as well as those used in the propensity score in the matched
sample by calculating standardized biases as well as testing for
differences between the two groups using t-tests; the maximum
standardized bias was b0.08, and all t-tests were not significant
(p N 0.40 for all comparisons). The HR and 95% CI for
INDUCED vs. NONE were calculated using a Cox proportional
hazards model in the matched sample. Standard errors were
computed using the sandwich (robust covariance matrix)
estimation procedure based on the matched pairs. The same
covariates from the multivariable model were included to adjust
for any residual confounding. As a final check, we also divided
the patients into five subclasses (strata) based on their propensity
score and then estimated the effect of induction within each
subclass. The Cox model included the same covariates from the
multivariable model. An overall estimate of the hazard ratio was
then calculated by weighting each subclass estimate by the
number of induced patients. All analyses were performed using
SAS/STAT software version 9.2 (SAS Institute Inc., Cary, NC).
3. Results
3.1. Study cohort
Of 23,951 patients listed in the registry, a total of 1721 met
all of the inclusion/exclusion criteria and were included in theTable 1
Flowsheet of study inclusion and exclusion criteria.
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Multiple induction agestudy (Table 1). Overall, 791/1721 (46%) of the patients in
the analysis cohort received an antibody-based induction
agent (INDUCED). Among those patients, the majority
(65%) received basiliximab, while 25% received ALG,
ATG, or thymoglobulin. A smaller percentage (10%)
received alemtuzumab (Table 2).
A summary of demographic and clinical characteristics by
induction status is shown in Table 3. The mean patient age was
28.0 (SD = 9.7) years for the INDUCED group and 28.5
(SD = 9.5) years for the NONE group. As anticipated, the
cohort was predominately Caucasian, since CF has a much
higher predilection for that patient population. Chronic steroid
treatment prior to LTx was common (29%) with equivalent
frequency of use between the two groups. Patients in both
group had common characteristics of advanced lung disease
due to CF, with need for oxygen supplementation, malnutrition
measured by low BMI, and evidence of very severe obstruction
on pulmonary function testing. Most donor organs had
ischemic times of 4–6 h in both groups. A greater proportion
of patients who were not induced were transplanted before
May 1, 2005 (when the LAS system was implemented)
compared to those who were induced (38% vs. 30%; p =
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Table 3
Demographics by induction status.
Variable Level Antibody based induction agent p-Value
No (n = 930) Yes (n = 791)
Recipient age at transplant Mean(SD) 28.5 (9.5) 28 (9.7) 0.265
(Min, max) (7, 55) (7, 55)
Recipient race Caucasian 865 (93%) 762 (96%) 0.010
African American 18 (2%) 7 (1%)
Other 47 (5%) 22 (3%)
Donor race Caucasian 596 (64%) 524 (66%) 0.415
African American 146 (16%) 127 (16%)
Other 188 (20%) 140 (18%)
Donor/recipient race match No match 355 (38%) 279 (35%) 0.214
Match 575 (62%) 512 (65%)
Recipient gender F 459 (49%) 391 (49%) 0.975
M 471 (51%) 400 (51%)
Donor gender F 422 (45%) 364 (46%) 0.790
M 508 (55%) 427 (54%)
Donor/recipient gender match No match 315 (34%) 289 (37%) 0.248
Match 615 (66%) 502 (63%)
Transplant type Double 928 (N99%) 789 (N99%) N .999
Single 2 (b1%) 2 (b1%)
Serum creatinine at transplant Missing 14 2 0.231
Creatinine ≤ 2 902 (98%) 782 (99%)
Creatinine N 2 14 (2%) 7 (1%)
Chronic steroid use Missing 75 20 0.361
N 582 (68%) 541 (70%)
Y 273 (32%) 230 (30%)
Diabetes Missing 11 6 0.395
N 556 (61%) 459 (58%)
Y 363 (40%) 326 (42%)
CMV match Missing 34 29 0.006
No Match 510 (57%) 484 (64%)
Match 386 (43%) 278 (36%)
Calculated recipient BMI #Missing Missing = 3 Missing = 0 0.302
Mean(SD) 19.3 (3) 19.1 (2.6)
(Min, max) (5.1, 37.6) (12.6, 32.2)
Lung allocation score (LAS) at match time Missing 2 2 0.013
Pre-LAS (transplant before 5/1/2005) 353 (38%) 237 (30%)
28.3–36.6 140 (15%) 141 (18%)
36.6–40.0 143 (15%) 139 (18%)
40.0–47.2 149 (16%) 133 (17%)
47.2–95.2 143 (15%) 139 (18%)
Year of transplant 2001 88 (9%) 37 (5%) b .001
2002 81 (9%) 48 (6%)
2003 64 (7%) 66 (8%)
2004 86 (9%) 74 (9%)
2005 101 (11%) 55 (7%)
2006 98 (11%) 84 (11%)
2007 88 (9%) 70 (9%)
2008 76 (8%) 85 (11%)
2009 92 (10%) 98 (12%)
2010 102 (11%) 107 (14%)
2011 54 (6%) 67 (8%)
Ischemic time (hours) #Missing Missing = 63 Missing = 84 0.065
Mean(SD) 5.7 (1.6) 5.9 (1.6)
(Min, max) (1.1, 11.9) (1.2, 12)
O2 requirement at rest at transplant #Missing Missing = 69 Missing = 17 0.150
Mean(SD) 3.6 (3.5) 3.9 (3.9)
(Min, max) (0, 20) (0, 26.3)
FEV1 % predicted at transplant #Missing Missing = 56 Missing = 20 0.018
Mean(SD) 27.2 (14.5) 25.4 (12.6)
(Min, max) (5, 106) (8, 120)
FVC % predicted at transplant #Missing Missing = 49 Missing = 16 0.104
Mean(SD) 40.7 (13.8) 39.5 (12.9)
(Min, max) (11, 101) (12, 130)
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Table 4
Median survival time by induction status.
Group N Mean
follow-up
time (months)
Number
of events
(deaths)
Median
survival time
(months)
95% CI for
median
survival time
No induction 930 42.4 435 61.8 (55.8, 73.8)
Induction 791 41.4 270 93.8 (73.8, --)
Table 5
Summary of modeling results.
Model N Estimated HR:
induced vs.
no induction
95% CI p-Value
Minimally adjusted:
Contains recipient age,
year of transplant, baseline
hazard stratified by region.
1721 0.666 (0.565, 0.784) b0.001
Multivariable model:
Contains recipient age,
LAS, year of transplant,
ischemic time, gender,
steroid use, diabetes, BMI,
O2 requirement at rest at
transplant, FEV1 %
predicted at transplant, and
FVC % predicted at
transplant. Baseline hazard
stratified by region.
1394 0.630 (0.521, 0.762) b0.001
Propensity score matched:
Contains the same
covariates as multivariable
model. Nearest neighbor
matching with
caliper = 0.2.
1232 0.668 (0.556, 0.802) b0.001
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Overall, 41% (705/1721) of patients died during the
post-transplant period. The data for survival time by induction
status is summarized in Table 4. Kaplan–Meier estimates of the
survival function for INDUCED vs. NONE are illustrated in
Fig. 1. The median survival within the INDUCED group was
93.8 months (95% CI: 73.8, --) as compared to 61.8 months
(95% CI: 55.8, 73.8) for the NONE group, log rank p-value
b0.001. Due to censoring, we were unable to calculate an upper
bound for the 95% CI for overall induction.
3.3. Cox proportional hazards modeling
The hazard ratio for INDUCED vs. NONE from the
minimally adjusted model was 0.666 (95% CI: 0.565, 0.784;
p b 0.001) (Table 5), indicating that being INDUCED had a
positive effect on survival. Results from the multivariable model
were consistent with those from the minimally adjusted model;
the hazard ratio for INDUCED vs. NONE from this model was
0.630 (95% CI: 0.521, 0.762; p b 0.001). In both the minimally
adjusted and multivariable models, there were no statistically
significant interactions between INDUCED and any other
covariate. In particular, the interaction between INDUCED and
year of transplant was not significant, indicating that the effect of
induction did not vary significantly over the study period.
Additionally, as a sensitivity analysis to the multivariable models,
propensity matching was utilized. The adjusted hazard ratio for
INDUCED vs. NONE among this subset of matched patients was
0.668 (95% CI: 0.556, 0.802; p b 0.001), which is consistentFig. 1. Kaplan–Meier estimates of post-lung transplant survival in recipients
with CF who received induction immunosuppression or not (Log rank
p-value b 0.0001).with results from the minimally adjusted and multivariable
model. The results from the matched analysis were consistent
with the model that split the data into five strata according to
propensity score (HR = 0.666; 95% CI: 0.534, 0.831; p b .001)
as well as the model that adjusted for propensity score (HR =
0.678; 95% CI: 0.573, 0.801; p b .001).
4. Discussion
In this analysis of the UNOS data registry, we have
demonstrated a survival benefit with the use of induction
immunosuppression in patients with CF undergoing LTx. Our
study used the largest currently available database of outcomes
from LTx, which includes data from all lung transplant centers
in the United States and limits potential biases inherent in
single center observational studies. We chose to analyze data in
CF patients aged 6–55 years, who received an initial cadaveric
LTx from 2001 to July, 2011. This allowed all patients to have
at least one year of follow-up in our data set obtained in July,
2012. We intentionally excluded patients who had received
OKT3 or daclizumab as these induction agents are no longer
available for clinical use. The demographic data of the cohort is
consistent with expected characteristics of patients with
advanced CF lung disease needing LTx; the group had
evidence of hypoxia, severe obstructive lung disease, and
malnutrition.
Recently, our group published data that showed a trend
towards (but not statistically significant) improved survival for
pediatric patients 6–17 years who received induction immuno-
suppression for LTx for all indications in that age group [15].
Approximately two-thirds of patients in this study had a
diagnosis of CF [15]. A limitation of the pediatric data is the
comparatively low numbers of transplantations performed in
109S. Kirkby et al. / Journal of Cystic Fibrosis 14 (2015) 104–110children, making it more challenging for analysis of survival to
reach statistical significance. Our present study captured data
from both children and adults with CF. We believe that, taken
together, our two studies suggest clinical benefit for induction
in patients with CF of all ages, although caution is always
justified in applying adult driven data to pediatric patients.
Jaksch and colleagues recently published retrospective data
from their large European lung transplant center demonstrating
improved overall survival and a lower risk of acute rejection in
CF LTx recipients who received induction with ATG [16]. This
group of investigators speculated that chronic inflammation from
CF lung disease stimulates the immune system which may have
adverse consequences post-transplant including acute cellular
rejection and the development of bronchiolitis obliterans
syndrome. Moreover, infectious risks may be counterbalanced
by the aggressive use of antimicrobial coverage in the
peri-transplant period. Although we did not specifically evaluate
the incidence of acute allograft rejection, bronchiolitis obliterans
syndrome, or major post-transplant infections in this cohort, our
present finding of a survival benefit with induction advances the
theory that profound inflammation inherent in CF may be a
driving force for adverse immunological events following LTx.
Therefore, suppressing the immune system with induction
therapy may reduce the ongoing innate inflammation in CF, but
future investigations should address the effect of this treatment on
acute and chronic allograft rejection in large cohorts of patients
with CF.
Our study was not specifically designed to analyze differences
in survival among individual agents used for induction immuno-
suppression. While the majority (65%) of patients in the
INDUCED group received basiliximab, there are insufficient
numbers of patients who received other agents to draw clear
conclusions on the optimal induction agent from this review of
registry data. The question of which antibody-based induction
agent confers the strongest clinical benefit in CF would be ideally
addressed by means of a prospective, randomized controlled trial.
A limitation of this study is the inherent challenges of
retrospective collection of data from individual centers into
large registries. Inconsistent data reporting is possible and a
small percentage of patients had incomplete data recorded.
Furthermore, the UNOS registry does not include important
data specific to CF, such as genotype or presence of microbial
pathogens. Although it is common to use antimicrobial agents
aimed at known chronic respiratory pathogens in CF patients
immediately after LTx, this practice is not standardized with
variation existing across centers. The antimicrobial agents used
in the peri-transplant period are not included in the UNOS data
registry. Therefore we cannot perform an analysis to evaluate
the effect of antimicrobial therapy following induction and
LTx. Finally, our analysis included both adults and children.
Although we found no strong evidence that the effect of
induction was different for adults compared to children (by
testing the interaction between recipient age and induction), we
acknowledge that there may be differences between the two
cohorts. Due to the limited number of children in our study, we
were unable to separate out adults and children into separate
models.In conclusion, this analysis of data from the UNOS registry
suggests a survival benefit of induction immunosuppression in
patients with CF undergoing LTx. Future research is needed to
determine if a specific induction agent is superior to others with
regard to overall survival and the incidence of rejection and
infectious complications.Author participation
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